U.S. License Holder:
Merck Sharp Dohme
Date of License:
March-26-2024
Last Update:
Apr-15-2026
FDA-Approved Indications
WINREVAIR (sotatercept-csrk) is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death.
